Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt No Debt
TBIO's Cash-to-Debt is ranked higher than
57% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. TBIO: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
TBIO' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.43
TBIO's Equity-to-Asset is ranked lower than
99.99% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. TBIO: 0.43 )
Ranked among companies with meaningful Equity-to-Asset only.
TBIO' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.43  Med: 0.43 Max: 0.43
Current: 0.43
Interest Coverage No Debt
TBIO's Interest Coverage is ranked lower than
54% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. TBIO: No Debt )
Ranked among companies with meaningful Interest Coverage only.
TBIO' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Altman Z-Score: -0.75
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -51058.40
TBIO's Operating Margin % is ranked lower than
99.99% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. TBIO: -51058.40 )
Ranked among companies with meaningful Operating Margin % only.
TBIO' s Operating Margin % Range Over the Past 10 Years
Min: -51058.4  Med: 0 Max: 0
Current: -51058.4
-51058.4
0
Net Margin % -45146.64
TBIO's Net Margin % is ranked lower than
99.99% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. TBIO: -45146.64 )
Ranked among companies with meaningful Net Margin % only.
TBIO' s Net Margin % Range Over the Past 10 Years
Min: -45146.64  Med: 0 Max: 0
Current: -45146.64
-45146.64
0
ROA % -63.03
TBIO's ROA % is ranked higher than
51% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. TBIO: -63.03 )
Ranked among companies with meaningful ROA % only.
TBIO' s ROA % Range Over the Past 10 Years
Min: -63.03  Med: -22.94 Max: -12.99
Current: -63.03
-63.03
-12.99
ROC (Joel Greenblatt) % -1692.94
TBIO's ROC (Joel Greenblatt) % is ranked lower than
62% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. TBIO: -1692.94 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
TBIO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1692.94  Med: -956.8 Max: -551.59
Current: -1692.94
-1692.94
-551.59
» TBIO's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

TBIO Guru Trades in Q3 2016

Jim Simons 219,900 sh (+101.93%)
» More
Q4 2016

TBIO Guru Trades in Q4 2016

Jim Simons 383,800 sh (+74.53%)
» More
Q1 2017

TBIO Guru Trades in Q1 2017

Jim Simons Sold Out
» More
Q2 2018

TBIO Guru Trades in Q2 2018

Seth Klarman 1,923,076 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with TBIO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Translate Bio Inc does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2833
Compare: » details
Headquarter Location:


Ratios

vs
industry
vs
history
PB Ratio 2.30
TBIO's PB Ratio is ranked lower than
99.99% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. TBIO: 2.30 )
Ranked among companies with meaningful PB Ratio only.
TBIO' s PB Ratio Range Over the Past 10 Years
Min: 1.93  Med: 2.6 Max: 4.04
Current: 2.3
1.93
4.04
PS Ratio 1320.00
TBIO's PS Ratio is ranked lower than
99.99% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. TBIO: 1320.00 )
Ranked among companies with meaningful PS Ratio only.
TBIO' s PS Ratio Range Over the Past 10 Years
Min: 1108  Med: 1492 Max: 2314
Current: 1320
1108
2314
EV-to-EBIT -1.13
TBIO's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. TBIO: -1.13 )
Ranked among companies with meaningful EV-to-EBIT only.
TBIO' s EV-to-EBIT Range Over the Past 10 Years
Min: -2.9  Med: -1.4 Max: -0.7
Current: -1.13
-2.9
-0.7
EV-to-EBITDA -1.14
TBIO's EV-to-EBITDA is ranked lower than
99.99% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. TBIO: -1.14 )
Ranked among companies with meaningful EV-to-EBITDA only.
TBIO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -2.9  Med: -1.4 Max: -0.7
Current: -1.14
-2.9
-0.7
EV-to-Revenue 574.96
TBIO's EV-to-Revenue is ranked lower than
99.99% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. TBIO: 574.96 )
Ranked among companies with meaningful EV-to-Revenue only.
TBIO' s EV-to-Revenue Range Over the Past 10 Years
Min: 348.1  Med: 703.4 Max: 1463.9
Current: 574.96
348.1
1463.9
Current Ratio 16.70
TBIO's Current Ratio is ranked higher than
56% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. TBIO: 16.70 )
Ranked among companies with meaningful Current Ratio only.
TBIO' s Current Ratio Range Over the Past 10 Years
Min: 1.69  Med: 5.22 Max: 16.7
Current: 16.7
1.69
16.7
Quick Ratio 16.70
TBIO's Quick Ratio is ranked higher than
58% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. TBIO: 16.70 )
Ranked among companies with meaningful Quick Ratio only.
TBIO' s Quick Ratio Range Over the Past 10 Years
Min: 1.69  Med: 5.22 Max: 16.7
Current: 16.7
1.69
16.7

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 220.00
TBIO's Price-to-Tangible-Book is ranked lower than
99.99% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. TBIO: 220.00 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
TBIO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 220  Med: 370.37 Max: 370.37
Current: 220
220
370.37
Price-to-Median-PS-Value 0.88
TBIO's Price-to-Median-PS-Value is ranked lower than
99.99% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. TBIO: 0.88 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TBIO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.88  Med: 1.34 Max: 1.34
Current: 0.88
0.88
1.34
Earnings Yield (Greenblatt) % -88.82
TBIO's Earnings Yield (Greenblatt) % is ranked lower than
70% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. TBIO: -88.82 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TBIO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -146.7  Med: -72.6 Max: -34.9
Current: -88.82
-146.7
-34.9

More Statistics

Revenue (TTM) (Mil) $0.24
EPS (TTM) $ -6.75
52-Week Range $5.00 - 16.60
Shares Outstanding (Mil)45.14

Piotroski F-Score Details

Piotroski F-Score: ----
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}